Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ARQ 531 |
| Trade Name | |
| Synonyms | ARQ531|ARQ-531|Nemtabrutinib|MK-1026|MK 1026|MK1026 |
| Drug Descriptions |
ARQ 531 is an ATP-competitive BTK inhibitor with activity against wild-type BTK and BTK C481S, which may inhibit migration and viability of tumor cells (PMID: 30093506, PMID: 31992353). |
| DrugClasses | BTK inhibitor 38 |
| CAS Registry Number | 2095393-15-8 |
| NCIT ID | C138066 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ARQ 531 | ARQ 531 | 1 | 4 |
| ARQ 531 + Lisocabtagene maraleucel | ARQ 531 Lisocabtagene maraleucel | 0 | 1 |
| ARQ 531 + Pembrolizumab | ARQ 531 Pembrolizumab | 0 | 1 |
| ARQ 531 + Rituximab | ARQ 531 Rituximab | 0 | 1 |
| ARQ 531 + Venetoclax | ARQ 531 Venetoclax | 0 | 1 |
| ARQ 531 + VLS-101 | ARQ 531 VLS-101 | 0 | 1 |